Wire Stories
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)
CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–$BGNE #BTKi—BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines...